Bundibugyo Virus vs Ebola (Zaire) Virus

Search for "the Ebola vaccine" during the 2026 outbreak and you will get an answer about a different virus. Ervebo, Inmazeb and Ebanga are all licensed against Zaire ebolavirus. The outbreak in DRC is Bundibugyo virus. This page sets the two species side by side — discovery, outbreak record, lethality, and the countermeasure gap — and says exactly what is known, and not known, about whether the Zaire products work.

Sources: CDC History of Ebola Outbreaks and clinical guidance, WHO Disease Outbreak News 603–617, FDA labels, Towner et al. 2008, Falzarano et al. 2011, Lhomme et al. 2026, Izudi & Bajunirwe 2024, CDC MMWR 2026. Data as of September 12, 2026 · Last reviewed: November 1, 2026.

Why This Distinction Decides What Medicine Is Available

Six species of Orthoebolavirus are recognised; four are known to infect people. Every approved Ebola countermeasure in the world targets exactly one of them.

The gap in one sentence. CDC's clinical guidance (page dated May 27, 2026) states that "there are no FDA-approved treatments or vaccine for infection with the other three orthoebolaviruses that are known to cause disease in humans — Bundibugyo virus, Tai Forest virus, and Sudan virus." The 2026 DRC outbreak — the second-largest Ebola outbreak ever recorded, with 10,467 confirmed cases and 5,103 confirmed deaths as of October 31, 2026 (CDC) — is Bundibugyo virus.

Side by side

  Ebola (Zaire) virus Bundibugyo virus
Species name Orthoebolavirus zairense (formerly Zaire ebolavirus) Orthoebolavirus bundibugyoense (formerly Bundibugyo ebolavirus)
First identified 1976, Yambuku, near the Ebola River, in what is now DRC — 318 cases, 280 deaths November 2007, Bundibugyo District, western Uganda; identified by pyrosequencing as a new species "distantly related" to Taï Forest virus (Towner et al., 2008)
Outbreak record Most of the large ones: 1976 Yambuku, 1995 Kikwit, 2014–16 West Africa (28,610 cases / 11,308 deaths per CDC), 2018–20 DRC, 2025 Kasai Two small outbreaks before 2026 — 2007–08 Uganda and 2012 Isiro, DRC — then the 2026 DRC outbreak, more than thirty times their combined total
CDC's lethality summary "up to 90% of cases are fatal" without treatment "about 30%"
Pooled CFR 1976–2022 66.6% (95% CI 55.9–76.8) 32.8% (95% CI 25.8–40.2)
Licensed vaccine Ervebo (rVSV-ZEBOV), FDA-approved December 2019; indicated for prevention of disease caused by Zaire ebolavirus in people 12 months and older None. Ervebo is being given under a WHO research protocol only; the one Bundibugyo-specific candidate in human trials is Moderna's mRNA-1469, in Phase 1
Licensed treatment Inmazeb (REGN-EB3) and Ebanga (ansuvimab), both FDA-approved 2020 for Orthoebolavirus zairense None. Both labels state efficacy "has not been established" for other species. Supportive care plus investigational drugs in the WHO PARTNERS trial
2026 outbreak role Not involved Causative species — 10,467 confirmed cases, 5,103 confirmed deaths in DRC (crude CFR ≈ 49%) as of October 31, 2026
CDC, History of Ebola Outbreaks (reviewed May 29, 2026) and Ebola Disease Basics (June 2, 2026); CDC Clinical Guidance for Ebola Disease (May 27, 2026); CDC Ebola Outbreak: Current Situation (September 14, 2026); FDA labels for Inmazeb (December 2025), Ebanga (August 2026) and Ervebo (current as of April 21, 2026); Towner JS, et al. PLoS Pathog 2008;4(11):e1000212; Izudi J, Bajunirwe F. J Infect Public Health 2024;17:25–34. The pooled Bundibugyo interval rests on under 200 cases and is correspondingly wide.

Why an antibody built for one species may not touch the other

All three approved products work through the same target: the viral surface glycoprotein. Inmazeb is three monoclonal antibodies that bind the Zaire glycoprotein and block cell entry; Ebanga is a single antibody against its receptor-binding region; Ervebo is a live vesicular stomatitis virus engineered to express the Zaire glycoprotein so the immune system learns that shape. Bundibugyo virus's glycoprotein is a different shape — different enough that in 2008 the sequence divergence was itself the reason a new species was declared, and the authors noted the implications for "ongoing efforts to develop effective antivirals and vaccines" (Towner et al., PLoS Pathogens 2008).

That is the mechanism behind every "not established" line on the FDA labels. It is not a paperwork gap waiting to be filled; it is a biological reason to expect reduced or absent activity, with no human data either way.

The Cross-Species Evidence: Monkeys in 2011, People in 2026

WHO is vaccinating health workers with a Zaire vaccine against a Bundibugyo outbreak. There is a reason that is not a shot in the dark — two pieces of evidence, measuring two different things, neither of which is an efficacy estimate.

In 2011, a team at Canada's National Microbiology Laboratory and the Galveston National Laboratory tested precisely this question in cynomolgus macaques. Animals were given a single dose of an rVSV vaccine expressing either the Zaire glycoprotein or the Taï Forest (then "Côte d'Ivoire") glycoprotein, then challenged with Bundibugyo virus. The Zaire-based vaccine produced 75% survival. The Taï Forest-based vaccine produced 33%, against 25% in mock-immunised animals — no better than nothing (Falzarano et al., J Infect Dis 2011;204 Suppl 3:S1082–9).

The authors' own conclusion is the careful one: this "demonstrates that monovalent rVSV-based vaccines may be useful against a newly emerging species; however, heterologous protection across species remains challenging and may depend on" how closely related the two species are. Bundibugyo virus is closer to Taï Forest virus phylogenetically than to Zaire — yet the Zaire vaccine was the one that worked. Cross-protection here is empirical, not predictable from the family tree.

Scale check: this is a non-human-primate study, in the small group sizes those studies use, of a vaccine given before challenge under laboratory conditions. Its value is that it measured survival after challenge — actual protection — which no human study of this question has done or ethically could.

The 2026 human data — antibodies, not protection

In 2026 the question was finally asked in people. Researchers analysed 179 serum samples from participants in the PREVAC randomised trial in West Africa, who had received either rVSVΔG-ZEBOV-GP (Ervebo) or the Ad26.ZEBOV/MVA-BN-Filo regimen, and tested them against glycoproteins from several filoviruses including Bundibugyo virus (Lhomme et al., N Engl J Med 2026;395:612–615).

Cross-reactive antibodies against Bundibugyo virus were detectable across every vaccine group, timepoint and age category — but at a fraction of the response to the virus the vaccines were built for. In rVSV recipients, the median Bundibugyo response at day 28 was a net MFI of 282 (IQR 164–644), against 1,788 (832–3,311) for the homologous Zaire Kikwit antigen — roughly a sixth. The Ad26/MVA regimen showed Bundibugyo responses that rose between day 28 and month 3. The authors conclude that licensed Zaire vaccines induce "detectable but quantitatively reduced" cross-reactive responses, which "support the plausibility of partial heterologous immunity."

The distinction that matters, and that most coverage blurs. The 2026 study measured whether antibodies bind Bundibugyo glycoprotein. It did not — and states it did not — assess whether vaccinated people are protected from Bundibugyo disease. Antibody cross-reactivity is a necessary condition for cross-protection, not a demonstration of it. So the honest summary of both studies together is: a Zaire vaccine protected most macaques in a 2011 challenge study, and produces measurable but much weaker antibody responses against Bundibugyo in people. Neither is an efficacy estimate, and that gap is exactly what WHO's research protocol exists to close.

This is the evidence base behind WHO's sequence of decisions in 2026: its Technical Advisory Group recommended on August 7 that Ervebo "be prioritized for inclusion in a randomized clinical trial"; SAGE concluded on August 19 that "available evidence remains insufficient to support the programmatic use of Ervebo for the prevention of BVD, and that its efficacy against BVD in humans remains unknown," recommending use only inside a research protocol; vaccination of health and frontline workers began in Kisangani on August 27, and 2,007 had been vaccinated across six health zones by September 6, 2026. The point of the protocol is to produce the efficacy evidence that neither the macaque challenge study nor the 2026 antibody study can supply. See Treatment & Vaccines for the products and trials in full.

What would cover both species — and why it isn't available

Antibody cocktails designed to neutralise several ebolavirus species do exist in development. MBP134, a two-antibody pan-ebolavirus cocktail, reversed Sudan virus disease in non-human primates from a single intravenous or intramuscular dose given as late as five days after exposure, and a half-life-extended version (MBP431) protected macaques challenged with Zaire virus (Kuang et al., Pathogens 2022;11(6):655). Other cross-reactive pairs have protected rodents and guinea pigs against Ebola and Sudan viruses (Liu et al., J Infect Dis 2023;228 Suppl 7:S691–700). None is FDA-approved, and none of these published animal studies used Bundibugyo virus as the challenge species.

So the honest state of play for a Bundibugyo patient in September 2026: supportive care, which demonstrably improves survival; remdesivir off-label, on the strength of 18 uncontrolled Ugandan patients and a negative result against Zaire virus in the PALM trial; and whatever the WHO-sponsored PARTNERS trial is testing, which WHO has not published — more than 300 patients enrolled across five facilities in Ituri as of September 10, 2026, with no interim result released.

Was Bundibugyo the "Milder" Ebola? The 2026 Answer Is Complicated

Until 2026 the answer was a confident yes. Bundibugyo virus was known from two outbreaks: 2007–08 in western Uganda, where CDC's history page gives 131 cases and 42 deaths (32%), the outbreak investigation by Wamala et al. found 42 laboratory-confirmed and 74 probable cases at 34%, and the clinical series by Roddy et al. counted 93 putative cases with 25% mortality; and 2012 in Isiro, DRC, analysed by Kratz et al. (PLoS One 2015;10(6):e0129333) across 52 patients, 18 of them treated in an Ebola treatment centre. Small outbreaks, fatality around a third, against two-thirds for Zaire virus.

The 2026 outbreak has produced a crude fatality rate of about 48% in DRC — above the upper bound of the 25.8–40.2% interval from the pooled historical data. Three explanations compete and the published counts cannot separate them:

  • Deaths lag cases. In a growing outbreak the crude ratio rises mechanically: WHO's own series went 17.7% (June 6) → 31.0% (July 1) → 44% (July 30) → 48.3% (September 7) as the epidemic grew.
  • Setting and access. The outbreak is centred on Ituri and North Kivu, conflict-affected provinces where patients reach care late. North Kivu's provincial CFR of 65.4% is under WHO investigation.
  • Detection. DRC's official count excludes probable cases, and suspected cases and deaths have been temporarily excluded pending investigation — which changes the denominator, not the disease.

The sharpest available contrast is not between species but between settings. Uganda's linked outbreak — same virus, same months — recorded 20 confirmed cases and 2 deaths (10%), with all 18 admitted patients receiving remdesivir under compassionate use in a Kampala treatment unit. The MMWR authors attribute the low fatality first to patients seeking care promptly, and note that both deaths were recognised as Ebola only near or after death (Mutegeki et al., MMWR 2026;75(35):551–3). Species sets the ceiling on what medicine exists; timing and setting appear to move the outcome more.

What this means if you are searching for "the Ebola vaccine." There is one, it is real, and it has a randomised efficacy estimate of 100% (95% CI 68.9–100) from the Guinea ring-vaccination trial — for Zaire ebolavirus. For the outbreak in the news in 2026, treat every claim about vaccines and antibodies as species-specific until you have checked which species it names. Our misinformation page covers the claims that most often get this wrong.

Frequently Asked Questions

Is there an Ebola vaccine for the 2026 outbreak?

Not an approved one. Ervebo is licensed for disease caused by Zaire ebolavirus; the 2026 outbreak is Bundibugyo virus. CDC states Ervebo "does not provide protection against other species of orthoebolaviruses," and WHO's SAGE concluded on August 19, 2026 that its efficacy against Bundibugyo virus disease in humans "remains unknown." WHO recommends use only inside a research protocol. Vaccination of health workers on that basis began August 27, 2026; 2,007 had been vaccinated by September 6.

What is the difference between Bundibugyo virus and Ebola virus?

Two different species in the same genus. Ebola virus (O. zairense) was identified in 1976 near the Ebola River and caused most of the large outbreaks, including West Africa 2014–16. Bundibugyo virus (O. bundibugyoense) was discovered in 2007 in western Uganda and was distinct enough to require a new species. Historically Bundibugyo virus was the less lethal — pooled CFR 32.8% against 66.6% — but the 2026 DRC outbreak has run at a crude 48%. The practical difference is that every licensed vaccine and antibody targets the Zaire species.

Do Inmazeb and Ebanga work against Bundibugyo virus?

Unknown, and not approved for it. Both FDA labels state that efficacy "has not been established for other species of the Orthoebolavirus and Orthomarburgvirus genera." Both bind the Zaire glycoprotein; Bundibugyo virus's differs. No human data have been published. Care in the 2026 outbreak rests on early supportive treatment plus investigational drugs inside the WHO PARTNERS trial.

Which Ebola species is the most deadly?

Ebola (Zaire) virus on the pooled record — 66.6% (95% CI 55.9–76.8) across 1976–2022, against 48.5% for Sudan virus and 32.8% for Bundibugyo virus (Izudi & Bajunirwe, 2024); CDC summarises it as fatal in "up to 90% of cases" untreated. But the ranking is not fixed. The 2026 Bundibugyo outbreak in DRC is running at about 48%, above Bundibugyo's historical interval, while the linked Uganda cases treated early in Kampala saw 2 deaths in 20 confirmed cases.

Are Sudan virus and Taï Forest virus also uncovered?

Yes. CDC's clinical guidance names all three of the non-Zaire human-infecting species — Bundibugyo, Taï Forest and Sudan viruses — as having no FDA-approved treatment or vaccine. Sudan virus has caused repeated Ugandan outbreaks (2000 Gulu, 2011, 2012, 2022, 2025) at a pooled 48.5% fatality; Taï Forest virus is known from a single non-fatal human case in Côte d'Ivoire in 1994. The countermeasure gap described on this page is therefore not specific to 2026 — it is the standing state of Ebola medicine for three of the four species that infect people.

Sources & References

  1. Towner JS, Sealy TK, Khristova ML, et al. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008;4(11):e1000212. doi:10.1371/journal.ppat.1000212
  2. Lhomme E, Wiedemann A, Ayouba A, et al. Cross-reactive Bundibugyo antibody responses after receipt of licensed Ebola vaccines. N Engl J Med 2026;395:612–615. doi:10.1056/NEJMc2608018
  3. Falzarano D, Feldmann F, Grolla A, et al. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis 2011;204 Suppl 3:S1082–9. doi:10.1093/infdis/jir350
  4. Kratz T, Roddy P, Tshomba Oloma A, et al. Ebola virus disease outbreak in Isiro, Democratic Republic of the Congo, 2012: signs and symptoms, management and outcomes. PLoS One 2015;10(6):e0129333. doi:10.1371/journal.pone.0129333
  5. Kuang E, Cross RW, McCavitt-Malvido M, et al. Reversion of ebolavirus disease from a single intramuscular injection of a pan-ebolavirus immunotherapeutic. Pathogens 2022;11(6):655. doi:10.3390/pathogens11060655
  6. Liu G, He S, Chan M, et al. A pan-ebolavirus monoclonal antibody cocktail provides protection against Ebola and Sudan viruses. J Infect Dis 2023;228(Suppl 7):S691–700. doi:10.1093/infdis/jiad205
  7. Izudi J, Bajunirwe F. Case fatality rate for Ebola disease, 1976–2022: a meta-analysis of global data. J Infect Public Health 2024;17:25–34. doi:10.1016/j.jiph.2023.10.020
  8. Mutegeki M, et al. Notes from the Field: Clinical characteristics of patients with Ebola disease caused by Bundibugyo virus — Uganda, 2026. MMWR 2026;75(35):551–3. doi:10.15585/mmwr.mm7535a2
  9. Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics (PALM). N Engl J Med 2019;381:2293–303. doi:10.1056/NEJMoa1910993
  10. Henao-Restrepo AM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease (Ebola Ça Suffit!). Lancet 2017;389:505–18. doi:10.1016/S0140-6736(16)32621-6
  11. Centers for Disease Control and Prevention. Clinical Guidance for Ebola Disease. Page dated May 27, 2026. cdc.gov/ebola/hcp/clinical-guidance
  12. Centers for Disease Control and Prevention. History of Ebola Outbreaks (reviewed May 29, 2026) and Ebola Disease Basics (June 2, 2026). cdc.gov/ebola/outbreaks
  13. Centers for Disease Control and Prevention. Ebola Outbreak: Current Situation. Page dated September 14, 2026. cdc.gov/ebola/situation-summary
  14. World Health Organization. Disease Outbreak News 615 (August 14), 616 (August 28), 617 (September 10, 2026): Ebola disease caused by Bundibugyo virus — Democratic Republic of the Congo. who.int/…/2026-DON617
  15. U.S. Food and Drug Administration. INMAZEB prescribing information (December 2025); EBANGA prescribing information (August 2026); ERVEBO (content current as of April 21, 2026). fda.gov/vaccines-blood-biologics/ervebo
  16. ClinicalTrials.gov. NCT07737717 — mRNA-1469, Bundibugyo virus vaccine, Phase 1. clinicaltrials.gov/study/NCT07737717